← Leaderboards
Kevin S Harrod
Lovelace Biomedical &Environmental Res
$6,939,116
Attributed
$9,410,579
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $964.4K · FY2005–23$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$9,410,579 · 5
By mechanism
R01$9,012,150 · 4
K02$398,429 · 1
Top collaborators
- Caroline A Owen5 shared
- Bruce D Levy2 shared
Most similar at Lovelace Biomedical &Environmental Res
Same institution · by research overlap
- Mohan L. Sopori$5,389,234
- Yohannes Tesfaigzi$22,872,420
Others in their field
Top investigators on “Virus Diseases”
- Barton F Haynes · Duke University$305,832,186
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$274,342,142
- Lawrence Corey · Fred Hutchinson Cancer Center$271,990,515
- Richard Webby · St. Jude Children'S Research Hospital$264,105,723
- David Heimbrook · Leidos Biomedical Research, Inc.$262,417,885
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$252,117,999
Research focus
Virus DiseasesLaboratory MouseLungMediatingInflammationProteinsIn VitroPharmaceutical PreparationsImmunityVaccinesInfluenzaInfluenza A VirusRespiratory InfectionsLinkRespiratory EpitheliumSecretory ProteinGenetically Modified AnimalsPhospholipase InhibitorMouse ModelAttenuatedAirway EpitheliumLiquid SubstanceInjuryIn Vivo
Grant awards (23)
Influenza regulation of epithelial pneumococcal host defense.$371,250
R01 · FY2023 · HL · contact PI
Influenza regulation of epithelial pneumococcal host defense.$371,250
R01 · FY2022 · HL · contact PI
Influenza regulation of epithelial pneumococcal host defense.$371,250
R01 · FY2021 · HL · contact PI
Influenza regulation of epithelial pneumococcal host defense.$371,250
R01 · FY2020 · HL · contact PI
Targeting MMP9 to Improve Outcomes in Serious Influenza Infections$850,154
R01 · FY2018 · AI · contact PI
Targeting MMP9 to Improve Outcomes in Serious Influenza Infections$955,998
R01 · FY2017 · AI · contact PI
Targeting MMP9 to Improve Outcomes in Serious Influenza Infections$964,377
R01 · FY2016 · AI · contact PI
Targeting MMP9 to Improve Outcomes in Serious Influenza Infections$717,682
R01 · FY2015 · AI · contact PI
Targeting MMP9 to Improve Outcomes in Serious Influenza Infections$852,665
R01 · FY2014 · AI · contact PI
Lung Transcriptional Regulation During Disease$84,465
K02 · FY2007 · HL · contact PI
CCSP Promoter Function and Tumor Necrosis Factor$487,274
R01 · FY2006 · HL · contact PI
Lung Transcriptional Regulation During Disease$82,004
K02 · FY2006 · HL · contact PI
CCSP Promoter Function and Tumor Necrosis Factor$400,000
R01 · FY2005 · HL
CCSP Promoter Function and Tumor Necrosis Factor$99,000
R01 · FY2005 · HL
Lung Transcriptional Regulation During Disease$79,617
K02 · FY2005 · HL
CCSP Promoter Function and Tumor Necrosis Factor$400,000
R01 · FY2004 · HL
Lung Transcriptional Regulation During Disease$77,297
K02 · FY2004 · HL
CCSP Promoter Function and Tumor Necrosis Factor$400,000
R01 · FY2003 · HL
CCSP IN INNATE DEFENSE AGAINST LUNG VIRAL INFECTION$350,000
R01 · FY2003 · HL
Lung Transcriptional Regulation During Disease$75,046
K02 · FY2003 · HL
CCSP IN INNATE DEFENSE AGAINST LUNG VIRAL INFECTION$350,000
R01 · FY2002 · HL
CCSP IN INNATE DEFENSE AGAINST LUNG VIRAL INFECTION$350,000
R01 · FY2001 · HL
CCSP IN INNATE DEFENSE AGAINST LUNG VIRAL INFECTION$350,000
R01 · FY2000 · HL